SCHEMBL931868

SCHEMBL931868

O=C(O)[C@@H]1C[C@@H](Cc2ccccc2)CN1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.54
GRIK1 P39086 6/20 0.52
ARG1 P05089 1/20 0.49
F2 P00734 3/20 0.47
MASP2 O00187 2/20 0.47
GBA1 P04062 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
ALOX15 P16050 1/20 0.43
CYP2C19 P33261 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3190846 1.00 HRH3 (0.54) HRH3GRIK1ARG1F2MASP2
SCHEMBL199034 1.00 HRH3 (0.54) HRH3GRIK1ARG1F2MASP2
SCHEMBL22536533 1.00 HRH3 (0.54) HRH3GRIK1ARG1F2MASP2
SCHEMBL199035 1.00 HRH3 (0.54) HRH3GRIK1ARG1F2MASP2
SCHEMBL19292680 1.00 HRH3 (0.54) HRH3GRIK1ARG1F2MASP2
SCHEMBL1706921 1.00 HRH3 (0.54) HRH3GRIK1ARG1F2MASP2
Hydrochloric Acid SCHEMBL15718411 0.98 GRIK1 (0.53) HRH3GRIK1ARG1F2MASP2
Hydrochloric Acid SCHEMBL7375374 0.98 GRIK1 (0.53) HRH3GRIK1ARG1F2MASP2
Hydrochloric Acid SCHEMBL7375375 0.98 GRIK1 (0.53) HRH3GRIK1ARG1F2MASP2
SCHEMBL23452209 0.91 GRIK1 (0.51) HRH3GRIK1ARG1F2MASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4274838-B1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LTD (GB) 2024-09-25 EP claimed
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2024-04-04 US claimed
CN-117529489-A Bicyclic peptide ligands specific for NK cells 拜斯科技术开发有限公司 2024-02-06 CN claimed
EP-4274838-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BicycleTx Limited (GB) 2023-11-15 EP claimed
WO-2022148974-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2022-07-14 WO claimed
EP-3697208-B1 HIGH-FIDELITY LONG-TERM STORAGE OF BIOLOGICAL MATERIAL CENTRE NAT RECH SCIENT (FR) 2026-04-22 EP disclosed
EP-4687443-A1 METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE Genepep (FR) 2026-02-11 EP disclosed
US-12250944-B2 High-fidelity long-term storage of biological material CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2025-03-18 US disclosed
CN-113453724-B Sulfonylmaleimide-based linkers and corresponding conjugates 皮埃尔法布雷医药公司 2025-02-25 CN disclosed
US-20250032603-A1 EXPRESSION OF THE SPIKE S GLYCOPROTEIN OF SARS-COV-2 FROM AVIAN PARAMYXOVIRUS TYPE 3 (APMV3) THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-01-30 US disclosed
US-20240350657-A1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES PIERRE FABRE MEDICAMENT (FR) 2024-10-24 US disclosed
WO-2024208878-A1 METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE GENEPEP (FR) 2024-10-10 WO disclosed
WO-2010144344-A2 MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2010-12-16 WO disclosed
WO-2010023295-A1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-03-04 WO disclosed
WO-2009143153-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2009-11-26 WO disclosed
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-26 US disclosed
EP-2099778-A2 AMIDO ANTI-VIRAL COMPOUNDS Smithkline Beecham Corporation (US) 2009-09-16 EP disclosed
US-20080249030-A1 Age Inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2008-10-09 US disclosed
US-20080181866-A1 Amido Anti-viral Compounds GENELABS TECHNOLOGIES, INC. 2008-07-31 US disclosed
WO-2008064218-A2 AMIDO ANTI-VIRAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS PBK, KLRK1, MICA HRH3 1986/4885GRIK1 681/4885ARG1 836/4885
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 HRH3 1/4885GRIK1 260/4885ARG1 32/4885
US-20080181866-A1 Amido Anti-viral Compounds ZC3HAV1, U2SURP, ZC3HAV1L HRH3 1525/4885GRIK1 1977/4885ARG1 102/4885
US-20240350657-A1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES STS, SULT1E1, CD44 HRH3 1878/4885GRIK1 2060/4885ARG1 3332/4885
US-20080249030-A1 Age Inhibitors CFH, XPA, XPNPEP1 HRH3 202/4885GRIK1 3739/4885ARG1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.